Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4817809 | 0.86 | NPC1 (0.37) | NPC1MAPTCDC7PIM1CDK9 | |
| SCHEMBL29959046 | 0.86 | NPC1 (0.37) | NPC1MAPTCDC7PIM1CDK9 | |
| SCHEMBL30443412 | 0.85 | NPC1 (0.39) | NPC1MAPT | |
| SCHEMBL2241065 | 0.85 | NPC1 (0.36) | NPC1MAPT | |
| SCHEMBL15586644 | 0.83 | NPC1 (0.38) | NPC1MAPTCDC7PIM1CDK9 | |
| SCHEMBL31554406 | 0.83 | NPC1 (0.35) | NPC1MAPTCDC7PIM1CDK9 | |
| SCHEMBL23611883 | 0.82 | NPC1 (0.37) | NPC1MAPTCDC7PIM1CDK9 | |
| SCHEMBL25322201 | 0.82 | DGAT1 (0.36) | NPC1MAPTCDC7PIM1CDK9 | |
| SCHEMBL1837871 | 0.82 | MAPT (0.38) | NPC1MAPTCDC7PIM1CDK9 | |
| SCHEMBL30509494 | 0.82 | DGAT1 (0.36) | NPC1MAPTCDC7PIM1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473284-B2 | Small molecule inhibitors of ULK1 | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-11-18 | — | — | US | disclosed |
| US-20230117572-A1 | SMALL MOLECULE INHIBITORS OF ULK1 | MEMORIAL SLOAN KETTERING CANCER CENTER | 2023-04-20 | — | — | US | disclosed |
| US-20230117572-A1 | SMALL MOLECULE INHIBITORS OF ULK1 | MEMORIAL SLOAN KETTERING CANCER CENTER | 2023-04-20 | — | — | US | disclosed |
| WO-2021138331-A2 | SMALL MOLECULE INHIBITORS OF ULK1 | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-07-08 | — | — | WO | disclosed |
| WO-2021138331-A2 | SMALL MOLECULE INHIBITORS OF ULK1 | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-07-08 | — | — | WO | disclosed |
| US-8957102-B2 | Heterocyclic compound as protein kinase inhibitor | NEOPHARM CO., LTD. (KR) | 2015-02-17 | — | — | US | disclosed |
| US-8957102-B2 | Heterocyclic compound as protein kinase inhibitor | NEOPHARM CO., LTD. (KR) | 2015-02-17 | — | — | US | disclosed |
| US-8957102-B2 | Heterocyclic compound as protein kinase inhibitor | NEOPHARM CO., LTD. (KR) | 2015-02-17 | — | — | US | disclosed |
| US-20120289509-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | NEOPHARM CO., LTD. (KR) | 2012-11-15 | — | — | US | disclosed |
| US-20120289509-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | NEOPHARM CO., LTD. (KR) | 2012-11-15 | — | — | US | disclosed |
| US-20120289509-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | NEOPHARM CO., LTD. (KR) | 2012-11-15 | — | — | US | disclosed |
| US-20110183983-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | NEOPHARM CO., LTD. (KR) | 2011-07-28 | — | — | US | disclosed |
| US-20110183983-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | NEOPHARM CO., LTD. (KR) | 2011-07-28 | — | — | US | disclosed |
| US-20110183983-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | NEOPHARM CO., LTD. (KR) | 2011-07-28 | — | — | US | disclosed |
| EP-2336123-A2 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | Neopharm Co., Ltd. (KR) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010044543-A2 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | 주식회사 네오팜 (KR) | 2010-04-22 | — | — | WO | disclosed |
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117572-A1 | SMALL MOLECULE INHIBITORS OF ULK1 | ULK1, ULK2, ULK3 | NPC1 2590/4885MAPT 868/4885CDC7 20/4885 |
| US-20110183983-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | MET, HGFAC, DMPK | NPC1 3268/4885MAPT 3424/4885CDC7 59/4885 |
| US-12473284-B2 | Small molecule inhibitors of ULK1 | ULK1, ULK2, ULK3 | NPC1 2590/4885MAPT 868/4885CDC7 20/4885 |
| US-20120289509-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | MET, HGFAC, DMPK | NPC1 3268/4885MAPT 3424/4885CDC7 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.